Patents by Inventor Jean Tang

Jean Tang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GENE THERAPY FOR RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA USING GENETICALLY CORRECTED AUTOLOGOUS KERATINOCYTES
    Publication number: 20240067926
    Abstract: Methods are provided for the cell-based delivery of collagen VII for the treatment of Epidermolysis Bullosa and corneal erosion. The disclosure also provides a composition and a pharmaceutical composition comprises, comprise, or alternatively consist essentially of, or yet further consist of a keratinocyte sheet or a corneal cell sheet.
    Type: Application
    Filed: November 3, 2023
    Publication date: February 29, 2024
    Inventors: Zurab Siprashvili, Ngon T. Nguyen, M. Peter Marinkovich, Jean Tang, Alfred T. Lane, Paul A. Khavari
  • GENE THERAPY FOR RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA USING GENETICALLY CORRECTED AUTOLOGOUS KERATINOCYTES
    Publication number: 20190382724
    Abstract: Methods are provided for the cell-based delivery of collagen VII for the treatment of Epidermolysis Bullosa and corneal erosion. The disclosure also provides a composition and a pharmaceutical composition comprises, comprise, or alternatively consist essentially of, or yet further consist of a keratinocyte sheet or a corneal cell sheet.
    Type: Application
    Filed: January 3, 2017
    Publication date: December 19, 2019
    Inventors: Zurab Siprashvili, Ngon T. Nguyen, M. Peter Marinkovich, Jean Tang, Alfred T. Lane, Paul A. Khavari
  • Topical itraconazole formulations and uses thereof
    Patent number: 9072660
    Abstract: Methods of transdermally delivering a therapeutic amount of a triazole-triazolone compound are provided, e.g. for the prevention or treatment of basal cell carcinoma (BCC) in a subject. A therapeutic level of a triazole-triazolone compound such as itraconazole is delivered transdermally to a subject. Also provided are topical triazole-triazolone compositions that find use in practicing the subject methods.
    Type: Grant
    Filed: September 7, 2012
    Date of Patent: July 7, 2015
    Assignees: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY, CHILDREN'S HOSPITAL & RESEARCH CENTER OAKLAND
    Inventors: Ervin H. Epstein, Jr., Jean Tang, Philip A. Beachy, Jayakumar Rajadas, James Kim
  • Topical Itraconazole Formulations and Uses Thereof
    Publication number: 20130109700
    Abstract: Methods of transdermally delivering a therapeutic amount of a triazole-triazolone compound are provided, e.g. for the prevention or treatment of basal cell carcinoma (BCC) in a subject. A therapeutic level of a triazole-triazolone compound such as itraconazole is delivered transdermally to a subject. Also provided are topical triazole-triazolone compositions that find use in practicing the subject methods.
    Type: Application
    Filed: September 7, 2012
    Publication date: May 2, 2013
    Inventors: Ervin H. Epstein, JR., Jean Tang, Philip A. Beachy, Jayakumar Rajadas, James Kim
  • Transgenic Animal Model of Cancer and Methods of Use
    Publication number: 20110030071
    Abstract: The invention features a transgenic mouse model of cancer, exemplified by basal cell carcinoma, which finds use in identification of anti-cancer drugs. The transgenic mouse is characterized by a heterozygous defect in a Patch gene (Ptch+/?) and an inducible suppression of functional p53.
    Type: Application
    Filed: April 9, 2009
    Publication date: February 3, 2011
    Inventors: Ervin H. Epstein, JR., Po-Lin So, Jean Tang
  • Methods and compositions for determining risk of treatment toxicity
    Patent number: 7465542
    Abstract: Methods are provided for determining whether a patient treated with an anti-proliferative agent is susceptible to toxicity. In practicing the subject methods, an expression profile for the transcriptional response to a therapy is obtained from the patient and compared to a reference profile to determine whether the patient is susceptible to toxicity. In addition, reagents and kits thereof that find use in practicing the subject methods are provided.
    Type: Grant
    Filed: October 14, 2003
    Date of Patent: December 16, 2008
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Gilbert Chu, Virginia G. Tusher, Jean Tang, Kerri Elyse Rieger, Wan-Jen Hong, Robert Tibshirani
  • Methods and compositions for determining risk of treatment toxicity
    Publication number: 20040152109
    Abstract: Methods are provided for determining whether a patient treated with an anti-proliferative agent is susceptible to toxicity. In practicing the subject methods, an expression profile for the transcriptional response to a therapy is obtained from the patient and compared to a reference profile to determine whether the patient is susceptible to toxicity. In addition, reagents and kits thereof that find use in practicing the subject methods are provided.
    Type: Application
    Filed: October 14, 2003
    Publication date: August 5, 2004
    Inventors: Gilbert Chu, Virginia G. Tusher, Jean Tang, Kerri Elyse Rieger, Wan-Jen Hong, Robert Tibshirani